Sun Pharmaceutical Share News - Latest Updates, Live News & More

Latest news about Sun Pharmaceutical

Sun Pharmaceutical Industries Sees Rs. 40.62 Crore Block Trade on NSE 2 days ago

Sun Pharmaceutical Industries Ltd. experienced a significant block trade on the National Stock Exchange (NSE). The transaction involved 255,995 shares at Rs. 1,586.70 per share, totaling Rs. 40.62 crore. This large, privately negotiated trade outside regular trading systems may indicate institutional interest or shifts in major shareholding patterns.

Sun Pharmaceutical Industries Executes Rs. 980 Crore Block Trade on NSE 6 days ago

Sun Pharma Promoter Pledges Additional Shares for Third-Party Loan Aug 04, 2025

Sun Pharma Reports Strong Q1 Results Amid US Drug Pricing Pressure Aug 01, 2025

Sun Pharma Plans Unloxcyt Launch for Advanced Skin Cancer, Reports Strong Q1 Growth Aug 01, 2025

More news about Sun Pharmaceutical

01Aug 25

Sun Pharma Reports Strong Q1 FY26 Performance with 10.1% Revenue Growth, Launches Leqselvi in US

Sun Pharmaceutical Industries Limited reported robust Q1 FY26 results with gross sales reaching ₹137,861.00 million, a 10.1% YoY increase. Adjusted net profit rose 5.7% to ₹29,961.00 million. India formulations sales grew 13.9%, US formulations by 1.4%, and Global Innovative Medicines business by 16.9%. The company launched Leqselvi in the US for severe alopecia areata. R&D investment was ₹9,029.00 million (6.5% of sales). A leadership transition was announced with Kirti Ganorkar set to become the new Managing Director.

01Aug 25

Sun Pharma Reports Strong Q1FY26 Results with 10.1% Revenue Growth

Sun Pharmaceutical Industries Limited reported robust financial results for Q1FY26. Gross sales reached ₹137,861.00 million, up 10.1% year-over-year. Adjusted net profit increased by 5.7% to ₹29,961.00 million, while EBITDA rose 19.2% to ₹43,017.00 million. The company showed strong performance across key markets, with India formulations growing 13.9%, US formulations up 1.4%, and Global Innovative Medicines segment growing 16.9%. Sun Pharma maintained its No. 1 ranking in the Indian pharmaceutical market with an 8.3% market share. R&D investments stood at ₹9,029.00 million, representing 6.5% of sales. The company's pipeline includes 542 approved ANDAs and 119 pending approval in the US market.

31Jul 25

Sun Pharma Reports Strong Q1 FY26 Growth, Reaffirms U.S. Market Commitment

Sun Pharmaceutical Industries Limited reported robust Q1 FY26 results with consolidated gross sales reaching ₹137,861.00 million, a 10.1% year-over-year growth. Adjusted net profit rose by 5.7% to ₹29,961.00 million. EBITDA increased by 19.2% to ₹43,017.00 million. The company maintained leadership in the Indian market, increasing market share to 8.3%. R&D investments were ₹9,029.00 million, representing 6.5% of sales. Sun Pharma launched LEQSELVI in the U.S. market for severe alopecia areata treatment. The company clarified it has no immediate plans to expand manufacturing operations in the U.S.

31Jul 25

Sun Pharma Reports 10.1% Revenue Growth in Q1FY26, Board Approves Committee Restructuring

Sun Pharmaceutical Industries Limited reported robust Q1FY26 results with consolidated gross sales of Rs. 137,861.00 million, up 10.1%. Adjusted net profit increased by 5.7% to Rs. 29,961.00 million. The company maintained its leadership in the Indian market with a 13.9% growth in formulation sales. US formulation sales grew by 1.4%, while global innovative medicines sales increased by 16.9%. The company faced exceptional charges of Rs. 8,180.00 million and announced board restructuring. Sun Pharma also launched the dermatology drug LEQSELVI in the US market.

21Jul 25

Sun Pharma's Tildrakizumab Achieves Primary Endpoint in Phase 3 Psoriatic Arthritis Trials

Sun Pharmaceutical Industries Limited announced successful Phase 3 clinical trials for Tildrakizumab 100 mg (ILUMYA®) in treating active psoriatic arthritis. The INSPIRE-1 and INSPIRE-2 studies met their primary endpoint, showing statistically significant improvement in ACR20 response rates at Week 24 compared to placebo. The trials involved over 800 adult patients across the US, Europe, and Asia. The safety profile was consistent with ILUMYA's known profile, with no new safety signals. Sun Pharma plans to use these results for potential regulatory submissions in the US for ILUMYA in treating active psoriatic arthritis.

17Jul 25

Sun Pharma Expands into China with New Subsidiary

Sun Pharmaceutical Industries Limited has established a new subsidiary, Sun Pharma (Hainan) Company Limited, in China. The subsidiary, registered on July 16, 2025, aims to localize products, collaborate with Chinese partners for production, and conduct sales in the Chinese market. Sun Pharma will maintain 100% ownership of the subsidiary, either directly or through existing subsidiaries. This move provides direct access to the Chinese pharmaceutical market, potentially reducing costs and improving regulatory compliance.

15Jul 25

Sun Pharma Launches LEQSELVI™ in US for Severe Alopecia Areata and Settles Litigation with Incyte

Sun Pharmaceutical Industries Limited has launched LEQSELVI™ (deuruxolitinib) in the United States for treating adults with severe alopecia areata. The company also reached a settlement with Incyte Corporation, resolving litigation related to LEQSELVI™. The agreement includes a limited, non-exclusive license for Sun Pharma and involves upfront and ongoing royalty payments to Incyte. LEQSELVI™, an oral JAK1 and JAK2 inhibitor, showed significant efficacy in clinical trials, with some patients achieving 80% scalp coverage in as fast as 8 weeks. Sun Pharma has introduced a patient support program offering eligible patients medication for as little as $0 for up to two years.

14Jul 25

Sun Pharma Launches LEQSELVI™ for Severe Alopecia Areata in US, Settles Patent Dispute with Incyte

Sun Pharmaceutical Industries Limited has launched LEQSELVI™ (deuruxolitinib) 8 mg tablets in the US for treating severe alopecia areata in adults. The drug showed rapid results in clinical trials, with some patients achieving significant hair regrowth in as little as 8 weeks. Sun Pharma also announced a settlement with Incyte Corporation regarding LEQSELVI™ litigation, including a limited, non-exclusive license for certain US patents. The company will pay Incyte an upfront amount and ongoing royalties. These developments are expected to strengthen Sun Pharma's position in the US pharmaceutical market, particularly in dermatology.

14Jul 25

Sun Pharma Launches Leqselvi for Severe Alopecia Areata Treatment in U.S.

Sun Pharmaceutical Industries Limited has launched LEQSELVI (deuruxolitinib) in the United States for treating severe alopecia areata in adults. LEQSELVI, an oral JAK1 and JAK2 inhibitor, showed significant efficacy in clinical trials, with one-third of patients regaining almost all hair by Week 24. The drug addresses a condition affecting up to 2.50% of the U.S. and global population. Sun Pharma has introduced the LEQSELVI SUPPORT Program to enhance patient access, offering eligible individuals medication for as little as $0 for up to two years. The company has also reached a settlement with Incyte Corporation regarding patent-related litigation.

14Jul 25

Sun Pharma Reaches Settlement with Incyte Corporation in LEQSELVI™ Litigation

Sun Pharmaceutical Industries Limited has reached a settlement and license agreement with Incyte Corporation regarding the litigation over LEQSELVI™ (deuruxolitinib). The settlement includes dismissal of pending litigation, mutual release of claims, and Incyte granting Sun Pharma a limited, non-exclusive license for oral deuruxolitinib in specific non-hematology-oncology indications, including alopecia areata, in the United States. Sun Pharma will pay Incyte an upfront amount and ongoing royalties until patent expiry. This resolution allows Sun Pharma to potentially expand its presence in the U.S. market for certain deuruxolitinib indications.

25Jun 25

Sun Pharma's Partner Withdraws Skin Cancer Treatment Application in Europe

Sun Pharmaceutical Industries Ltd's partner, Philogen S.P.A., has withdrawn the marketing authorization application for their jointly developed skin cancer drug, Nidlegy™, from the European Medicines Agency (EMA). The withdrawal is due to timing issues with data availability. Philogen intends to resubmit an updated application in the future, indicating ongoing commitment to the drug's development. This temporary setback may delay potential revenue from Nidlegy™ in Europe and require additional studies or data before resubmission.

16Jun 25

Sun Pharma's Halol Facility Faces FDA Scrutiny: 8 Observations Issued

Sun Pharmaceutical Industries Ltd's Halol facility in Gujarat underwent a U.S. FDA inspection from June 2 to June 13, resulting in a Form-483 with eight observations. The Form-483 indicates potential violations of the Food Drug and Cosmetic Act, though it's not a final determination of compliance. Sun Pharma must respond with a corrective action plan. The Halol facility has faced previous regulatory challenges, making this inspection significant for the company's U.S. business prospects. The company's response and ability to address these observations will be crucial for maintaining its position in the U.S. market.

16Jun 25

Sun Pharma's Halol Facility Receives FDA Form 483 with 8 Observations Following GMP Inspection

Sun Pharmaceutical's Halol facility has received a Form 483 from the US FDA, citing 8 observations following a GMP inspection. This comes after a previous warning letter and import alert for the same facility. The Halol plant remains under import alert since its last inspection in May 2022. Sun Pharma is expected to respond with a detailed corrective action plan to address the observations and work towards resolving the ongoing regulatory issues.

14Jun 25

FDA Inspection at Sun Pharma's Halol Plant Yields 8 Observations, Facility Remains Under Import Alert

Sun Pharmaceutical Industries Ltd's Halol facility in Gujarat has received a Form 483 from the US FDA following a GMP inspection from June 2-13. The form outlines eight observations, indicating potential GMP compliance issues. This development is significant as the facility is already under import alert due to a previous warning letter. Sun Pharma is expected to review and address these observations to ensure compliance with FDA standards. The Halol facility is crucial for Sun Pharma's US market supply, making resolution of these regulatory issues essential for the company's operations.

13Jun 25

Sun Pharma Announces Leadership Transition: Kirti Ganorkar Named New Managing Director, Dilip Shanghvi to Become Executive Chairman

Sun Pharmaceutical Industries Ltd has announced the appointment of Kirti Ganorkar as its new Managing Director, effective September 1, 2025, subject to shareholder approval. Ganorkar, who has been with the company since 1996, will oversee all business operations. Concurrently, founder Dilip Shanghvi will transition to the role of Executive Chairman of the Board. This leadership change aims to bring fresh perspectives while retaining experienced guidance in the company's strategic direction.

04Jun 25

Sun Pharma's SCD-044 Phase 2 Trial Falls Short of Primary Endpoint

Sun Pharmaceutical Industries Ltd announced that its Phase 2 clinical trial for SCD-044, a potential new medication, did not achieve its primary endpoint. This setback in the drug development process may impact the company's research and development outlook. Sun Pharma has not provided detailed information about next steps, but typical responses include reassessing the drug's potential, exploring alternative indications, or considering modifications to the compound.

03Jun 25

Sun Pharma Discontinues SCD-044 Drug After Failed Trials in Psoriasis and Atopic Dermatitis

Sun Pharmaceutical Industries Ltd has announced the discontinuation of its experimental drug SCD-044 following unsuccessful Phase 2 clinical trials for psoriasis and atopic dermatitis. The drug failed to meet the primary endpoint of 75% symptom improvement in both trials, involving 263 psoriasis patients and 250 atopic dermatitis patients. This represents a significant setback for Sun Pharma's research and development pipeline, leading to the decision to halt further development of SCD-044.

02Jun 25

Sun Pharma Projects Growth on New Launches Amid Profitability Challenges

Sun Pharmaceutical Industries expects mid-to-high single-digit revenue growth in FY26, driven by new product launches including Leqselvi and Unloxcyt. However, increased marketing expenses for specialty products and higher tax obligations may impact profitability. The company plans to invest 6-8% of sales in R&D. Despite a 19% decline in Q4 FY25 net profit due to higher taxes, revenue grew by 8% in the same quarter.

01Jun 25

Sun Pharma Unveils $100 Million Investment Plan for Specialty Products in FY26

Sun Pharmaceutical Industries plans to invest $100 million in FY26 to commercialize new specialty products, focusing on Unloxcyt and Leqselvi. The company aims for mid-to-high single-digit consolidated topline growth and will allocate 6-8% of sales to R&D. Sun Pharma is acquiring Checkpoint Therapeutics and seeking a partner for MM-II development. These strategic moves are aimed at strengthening its product pipeline and market position in the specialty pharmaceutical sector.

30May 25

Sun Pharma Completes Acquisition of Checkpoint Therapeutics

Sun Pharmaceutical Industries Ltd has successfully acquired Checkpoint Therapeutics, a company focused on developing cancer treatments. This strategic move is expected to expand Sun Pharma's oncology portfolio, enhance its R&D capabilities, and strengthen its position in the global pharmaceutical market. The acquisition could lead to synergies in research, development, and commercialization of cancer treatments. Specific financial details of the deal were not disclosed.

24May 25

Sun Pharma Sets Sights on Mid-to-High Single-Digit Revenue Growth for FY26

Sun Pharmaceutical Industries Ltd has announced its revenue growth target for fiscal year 2026, aiming for a mid-to-high single-digit increase. This projection factors in potential regulatory uncertainties in the crucial U.S. market. The company's strategy suggests a focus on sustainable expansion through diversification, innovation, market expansion, and operational efficiency. This cautious yet optimistic outlook reflects Sun Pharma's pragmatic approach to growth amid complex global pharmaceutical regulations.

23May 25

Sun Pharma Invests $25 Million in Pharmazz Inc, Increasing Stake to 22.7%

Sun Pharmaceutical Industries Ltd has agreed to invest up to $25 million in Pharmazz Inc, increasing its stake to 22.7%. The investment supports the development of two advanced drug candidates for stroke and shock. Sun Pharma gains options for licensing rights in certain markets, aligning with its strategy to expand its portfolio and market presence in specialty areas.

23May 25

Sun Pharma Q4 Profit Dips, Revenue Rises; Announces Dividend

Sun Pharmaceutical Industries Ltd reported mixed Q4 results. Net profit decreased to ₹21.50 billion from ₹26.50 billion year-over-year, falling short of market expectations. Revenue increased to ₹129.59 billion from ₹119.80 billion. The company reported an exceptional item of ₹3.62 billion and improved profit before tax of ₹36.20 billion. The board recommended a final dividend of ₹5.50 per equity share.

21May 25

Sun Pharma Q4 Preview: Revenue Growth Expected at 12.9%, Driven by gRevlimid Sales

Sun Pharmaceutical Industries Ltd is set to announce its Q4 results on Thursday. Analysts project a 12.9% YoY revenue increase to Rs 13,254.38 crore, driven by gRevlimid sales. Net profit is expected to rise 5.24% YoY to Rs 2,793.94 crore. US market revenues are anticipated to grow 10% YoY, with healthy growth in India and emerging markets. Investors will focus on R&D guidance, acquisition updates, and plant resolution progress.

20May 25

Sun Pharma Acquires Checkpoint Therapeutics for $616 Million, Bolstering Dermatology-Oncology Portfolio

Sun Pharmaceutical Industries has acquired Checkpoint Therapeutics for $616 million, including a $355 million upfront payment, $60 million contingent payment, and additional royalties. The acquisition, aimed at strengthening Sun Pharma's dermatology-oncology market position, brings key asset Unloxcyt to their portfolio. Macquarie views the deal as value accretive and has raised Sun Pharma's target price to Rs 2,135.00.

19May 25

Sun Pharma's BLU-U Device Upgrade Receives FDA Approval for Skin Treatment

Sun Pharmaceutical Industries has received FDA approval for an upgraded version of its BLU-U Blue Light Photodynamic Therapy device. The new model transitions from fluorescent tubes to LED technology, offering improved efficiency and usability in treating actinic keratosis, a pre-cancerous skin condition. This approval marks a significant advancement in Sun Pharma's medical device portfolio and reinforces its position in dermatological treatments.

16May 25

Sun Pharma's New Photodynamic Therapy Device Receives FDA Approval

Sun Pharmaceutical Industries Ltd. has received FDA approval for its next-generation Blu-U® Blue Light Photodynamic Therapy Illuminator, designed to treat actinic keratosis, a pre-cancerous skin condition. This approval enhances Sun Pharma's dermatology portfolio and reinforces its position in the global dermatology market. The device uses photodynamic therapy for treating pre-cancerous skin lesions, potentially improving patient care and treatment outcomes.

06May 25

Sun Pharma Appoints Jayashree Satagopan as New Chief Financial Officer

Sun Pharmaceutical Industries Ltd. has named Jayashree Satagopan as its new Chief Financial Officer. Satagopan will oversee financial operations, develop strategies, ensure regulatory compliance, and support growth initiatives for the leading Indian pharmaceutical company. This appointment marks a significant change in Sun Pharma's top management, potentially influencing the company's financial direction and performance in the competitive pharmaceutical industry.

24Apr 25

Sun Pharma and Moebius Medical Unveil Promising Results for Novel Osteoarthritis Treatment

Sun Pharmaceutical Industries and Moebius Medical have published two groundbreaking articles in Osteoarthritis and Cartilage journal, showcasing the potential of their novel osteoarthritis treatment, MM-II. A Phase 2b trial demonstrated that a single MM-II injection provided pain relief for up to 26 weeks in knee osteoarthritis patients. The treatment's unique mechanism forms a lubricative layer over cartilage surfaces, potentially reducing friction and slowing cartilage degeneration. MM-II has received Fast Track Designation from the FDA, and new data will be presented at OARSI 2025. The global market for knee osteoarthritis pain relief products is estimated at $2 billion with a 6.5% CAGR.

22Apr 25

Sun Pharma Shares Witness Significant Block Trade on NSE

Sun Pharmaceutical Industries Ltd. experienced a significant block trade on the National Stock Exchange (NSE), involving 90,708 shares valued at Rs. 15.81 crores. The trade was executed at Rs. 1,742.80 per share, representing a substantial portion of the day's trading volume. This transaction highlights ongoing interest in Sun Pharma's stock among large investors.

16Apr 25

Sun Pharma Sees Significant Block Trade on NSE

Sun Pharmaceutical Industries Ltd. experienced a significant block trade on the National Stock Exchange (NSE). The transaction involved 125,345 shares traded at Rs. 1,688.90 per share, totaling Rs. 21.17 crores. This large-scale trade has drawn attention from market observers and investors, potentially influencing market sentiment and stock price movements.

11Apr 25

Sun Pharma Wins Court Ruling, Clears Path for LEQSELVI Launch in U.S.

Sun Pharmaceutical Industries Ltd has secured a favorable ruling from the U.S. Court of Appeals, vacating a preliminary injunction that previously blocked the launch of its autoimmune disorder drug, LEQSELVI (deuruxolitinib), in the United States. The drug targets patchy hair loss. While litigation with Incyte Corporation continues, Sun Pharma is no longer restricted from launching LEQSELVI. The company will announce its launch plans for the drug in due course.

10Apr 25

Sun Pharma Wins US Court Appeal, Clears Path for LEQSELVI Launch

Sun Pharmaceutical Industries Ltd has secured a significant legal victory in the United States. The U.S. Court of Appeals for the Federal Circuit has vacated a preliminary injunction, allowing Sun Pharma to proceed with the launch of LEQSELVI™ (deuruxolitinib), its autoimmune-related hair loss drug. This decision, made on April 9, 2025, overturns a previous ruling by the U.S. District Court for the District of New Jersey. While litigation with Incyte Corporation continues, Sun Pharma is no longer restricted from launching LEQSELVI™ and will announce its launch plans in due course.

10Apr 25

Sun Pharma's Leqselvi Gets Green Light as US Court Vacates Injunction

Sun Pharmaceutical Industries Ltd has secured a significant legal victory in the United States. The U.S. Court of Appeals for the Federal Circuit vacated a preliminary injunction on April 9, 2025, allowing Sun Pharma to proceed with the launch of Leqselvi (deuruxolitinib), a treatment for severe alopecia areata. While litigation with Incyte Corporation continues, Sun Pharma is no longer restricted from launching the medication and will announce its launch plans soon.

07Apr 25

Sun Pharma Launches Fexuclue: A Novel Treatment for Erosive Esophagitis in India

Sun Pharmaceutical Industries Limited has introduced Fexuclue® (Fexuprazan), a novel potassium-competitive acid blocker (P-CAB) for treating Erosive Esophagitis in adults. The medication offers fast-acting, flexible dosing and long-lasting effects. A Phase 3 study showed over 95% efficacy in healing Erosive Esophagitis by 8 weeks. This launch addresses an unmet need in India, where GERD prevalence ranges from 7.60% to 30.00%. The product results from a collaboration with Daewoong Pharmaceutical Co Ltd.

01Apr 25

Sun Pharma Advanced Research Submits IND Application for Cancer Drug SBO-154 to FDA

Sun Pharma Advanced Research Company (SPARC) has submitted an Investigational New Drug (IND) application for SBO-154, a novel compound targeting advanced solid tumors, to the U.S. FDA. This submission paves the way for global Phase 1 clinical trials, potentially leading to new treatment options for cancer patients. The move underscores SPARC's commitment to oncology innovation and could strengthen its position in cancer drug development.

18Mar 25

Sun Pharma Completes CAD 4.5 Million Acquisition of Antibe Therapeutics

Sun Pharmaceutical Industries Limited has finalized its acquisition of Canadian firm Antibe Therapeutics Inc. through its subsidiary TARO Pharmaceuticals Inc. The deal, valued at CAD 4.5 million (approx. ₹27.45 crore), was completed on March 18, 2025. This strategic move aims to expand Sun Pharma's product portfolio and strengthen its presence in the North American market.

11Mar 25

Sun Pharma Acquires Checkpoint Therapeutics in $450 Million Deal to Boost Specialty Business

Sun Pharmaceutical Industries Ltd has agreed to acquire Checkpoint Therapeutics, Inc. for approximately $450 million. The deal, set to close in the second half of 2025, involves a cash payment of $4.10 per share plus potential contingent value rights of up to $0.70 per share. This acquisition aims to strengthen Sun Pharma's specialty business, particularly in dermatology, ophthalmology, and oncology. The key asset is cosibelimab, an anti-PD-L1 antibody in development for treating advanced cutaneous squamous cell carcinoma. The acquisition is expected to be earnings accretive within the first full year after closing.